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Background: There is general consensus internationally that unfair distribution of the benefits of research is exploitative
and should be avoided or reduced. However, what constitutes fair benefits, and the exact nature of the benefits and their
mode of provision can be strongly contested. Empirical studies have the potential to contribute viewpoints and
experiences to debates and guidelines, but few have been conducted. We conducted a study to support the
development of guidelines on benefits and payments for studies conducted by the KEMRI-Wellcome Trust programme in
Kilifi, Kenya.
Methods: Following an initial broad based survey of cash, health services and other items being offered during research
by all programme studies (n=38 studies), interviews were held with research managers (n=9), and with research staff
involved in 8 purposively selected case studies (n= 30 interviewees). Interviews explored how these ‘benefits’ were
selected and communicated, experiences with their administration, and recommendations for future guidelines. Data fed
into a consultative workshop attended by 48 research staff and health managers, which was facilitated by an external
ethicist.
Findings: The most commonly provided benefits were medical care (for example free care, and strengthened quality of
care), and lunch or snacks. Most cash given to participants was reimbursement of transport costs (for example to meet
appointments or facilitate use of services when unexpectedly sick), but these payments were often described by research
participants as benefits. Challenges included: tensions within households and communities resulting from lack of clarity
and agreement on who is eligible for benefits; suspicion regarding motivation for their provision; and confusion caused
by differences between studies in types and levels of benefits.
Conclusions: Research staff differed in their views on how benefits should be approached. Echoing elements of
international benefit sharing and ancillary care debates, some research staff saw research as based on goodwill and
partnership, and aimed to avoid costs to participants and a commercial relationship; while others sought to maximise
participant benefits given the relative wealth of the institution and the multiple community needs. An emerging middle
position was to strengthen collateral or indirect medical benefits to communities through collaborations with the Ministry
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Debates on the ethics of international health and health
research have shifted over the last twenty five years away
from a focus on the relevance and value of informed
consent, towards considering broader challenges such as
the potential for exploitation in international research,
the need to make research responsive to local needs of
host communities, and the implications of research for
international relations and law [1,2]. This shift is related
to growing recognition that focusing on the protection
of research participants through reviewing research pro-
posals before they begin is inadequate; that there is a
need to look beyond the design of studies and to see
how research is actually being conducted on the ground
[2]. The importance of social science studies for under-
standing the dilemmas that are faced and generated, and
the ethical implications of how these are resolved, have
begun to be highlighted [3]. Depending on their design,
such studies can fall within the spectrum of approaches
termed ‘empirical ethics’ [4,5], and may incorporate
deliberative elements [6].
Within this general movement in ethical focus, there
is consensus that unfair distribution of the benefits of
research is exploitative and that - as a moral wrong - it
should be minimised. One approach to doing this is to
provide ‘fair benefits’ to participants and their communi-
ties [7,8]. There is still debate over what constitutes fair
benefits, and over the appropriate balance in benefits
between micro level issues of justice and broader social
determinants of health at the macro level [7–13].
However, increasing benefits to participants and
communities involved in research is widely agreed as
one approach to minimize exploitation.
The fair benefits framework distinguishes between
benefits from both the conduct and results of research,
and between:
 direct benefits to those enrolled in the research (for
example diagnostic tests, distribution of medications
and evaluation services); and
 collateral or indirect benefits not targeted specifically
at those involved in the research (for example
providing antibiotics for respiratory infections,
health service provision, digging of bore holes for
clean water, or research capacity building) [7,8,14].
Beneficiaries of collateral benefits might be research
participants, other identifiable individuals such as
family members, or the general community.
In considering fair benefits for research, a widely
accepted ethical condition is that the research must pose
few risks to individual participants, or the benefits to
them should outweigh the risks [7]. Where potential
risks outweigh benefits to participants, the social valueof the research should justify the risks [15,16]. It is also
increasingly argued that the risk-benefit ratio for the
communities within which the research is conducted
should be favourable [15]. However, the exact nature of
the benefits that can and should be provided for various
studies in different settings, and their mode of provision,
remain ill-defined and often strongly debated. The
boundary between ‘benefits’ and obligations, for example
with regards to ancillary-care in health, is also complex
and contested [17–19], as will be returned to in the dis-
cussion of this paper.
The notion of undue inducement, and the paradoxical
relationship with exploitation, has received particular
attention in benefits debates. As Koen et al. [20] have
argued, inducement by itself can be ethically justifiable,
even if it contributes to participants doing something
that they might otherwise not have done. However
inducement becomes ‘undue’ where an excessive offer
distorts decision-making, leading to individuals partici-
pating against their better judgment. Also of concern
with regards to inducement is the potential to dispropor-
tionately attract the poor, and the fabrication of informa-
tion in order to access study benefits. The dilemma,
raised by Macklin (1989) and summarized by Ballantyne
is: ‘offer participants too little and they are exploited,
offer them too much and their participation may be un-
duly induced’ [21]; p 179. This paradox is particularly
stark in international collaborative research, where re-
search institutions and bodies may be relatively wealthy,
operating in and among relatively low income settings
and populations.
One specific form of benefit in research is payment of
cash. Cash payments which reimburse or compensate
for time and inconvenience are not considered benefits,
and are widely accepted in international guidelines. For
these forms of payment, the challenge is the limited
amount of operational guidance to set appropriate pay-
ment levels. More controversial are cash payments as
incentives to participate in research, or as appreciations
for contributions to the research [20]. The specific
additional concern about money as a benefit (beyond
undue inducement) is the potential to commercialize an
altruistic endeavor. Those in favour of financial pay-
ments argue that altruistic motives are not incompatible
with receiving pay, that research has long been commer-
cialized for other research stakeholders, and that partici-
pants are not only motivated by money [20]. A
particular concern expressed informally in low income
settings is that populations should not be deprived of
potential payments simply because of their poverty as
this leads to a double inequity: both poverty and inability
to benefit financially.
Debates on benefits and payments in all low income
settings are hampered by relatively little information on
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range of stakeholders’ views on current practice. An ex-
ception is work by Lairumbi et al. [22–24] which
explores perceptions of, and experiences with, benefits
among a diverse range of research stakeholders across
Kenya. In this paper we present a separate but comple-
mentary set of data. We explore views and experiences
with regards to benefits and payments from a diverse
range of studies conducted by one large and long-term
multi-disciplinary research programme in Kenya - the
Kenya Medical Research Institute (KEMRI)-Wellcome
Trust Research Programme in Kilifi - and consider the
implications for institutional guidelines aimed at ensuring
fair involvement of participants. We focus on the direct
and collateral ‘benefits’ (all cash, health services and other
items) offered to study participants and to community
members over the course of the conduct of studies, as
opposed to post study benefits, or aspirational benefits.Methods
KEMRI- Wellcome Trust Programme in Kilifi
The KEMRI-Wellcome Trust Programme is a collaboration
between the KEMRI Centre for Geographical Medicine
Research, Coast (CGMRC), and the Wellcome Trust, UK.
KEMRI is a parastatal organisation under the Ministry of
Health (MoH), with 10 research centres in Kenya, of which
the CGMRC is one of the largest. The KEMRI-Wellcome
Trust research programme (KEMRI/WT) was established
in 1989. It has grown enormously over the last twenty
years, now employing over 800 staff between sites in
Nairobi and Kilifi, and conducting a wide range of interdis-
ciplinary research including clinical, basic science, epi-
demiological and public heath aspects of major childhood
and adult diseases of concern in Kenya. A core aim of the
programme is strengthening regional capacity to conduct
and lead internationally competitive research.
This paper focuses on work conducted in the largest of
the two sites, Kilifi. Kilifi district is on the coast of Kenya,
with residents primarily from the Mijikenda ethnic group.
There are very high levels of poverty, and low levels of
literacy across the district. As described in greater detail
elsewhere [25], a key feature of the Kilifi work has been its’
deliberate development within a District Hospital, with
much research being carried out in a “real world environ-
ment” serving a rural community. The research centre
provides support to the hospital to ensure a good standard
of care is available to those using the departments where
research is conducted, regardless of their involvement in
research. This is a form of collateral benefit to the general
community as a result of the research programme having
a long-term presence in the area, with the additional
resources including medical and clinical officers, paediatric
drugs and equipment and a paediatric intensive care ward.Within the community, clinical services are supported at
specific government health centres and dispensaries.
Every study carried out by the programme is scrutinised
in advance by local and independent national and inter-
national scientific and ethical review committees. Over the
last ten years, informed by social science research activities
(see for example [25–29]), both programme wide and
study specific community engagement activities have been
strengthened. For example a large network of KEMRI
community representatives elected by community mem-
bers has been established, and the amount and type of
interactions between research staff and community leaders
and ‘ordinary’ community members has been increased.
Interactions have increased in communities and within
the research programme and hospital.
The research presented in this paper was initiated out of
an institutional interest in developing locally appropriate
guidance on benefits and payments for the diverse range of
studies conducted in Kilifi. From the outset, it was clear
that relatively high risk studies – such as phase 1 and 2a
trials - needed separate consideration with particularly care-
ful scrutiny on benefits and payments by the Ethics Review
Committee. These studies were therefore not discussed and
are not included in the considerations outlined in the rest
of this paper.
Methods
Data collection was in two main phases: an initial audit
of current practice and experiences and views from
front-line staff involved in distributing benefits; and a
workshop involving a wide range of research staff and
some MoH managers.
Audit of current practice
The audit involved an initial email survey followed by semi-
structured interviews with principal investigators and inter-
face staff involved in eight purposively selected case studies.
These data were supplemented by interviews with key infor-
mants expected to have relevant cross-study information.
Email survey
56 principal investigators leading active Kilifi based studies
were contacted to identify studies that were still in recruit-
ment, data collection, analysis or write-up stages. Semi-
structured questionnaires were filled for each of the 38 ac-
tive (sub) studies identified (n= 24 PIs). The questionnaire
for these studies covered: the nature of services, payments
and other items (‘benefits’) offered to participants, the
intended recipients of benefits, stage of study at which
benefits are given, and any community benefits.
In-depth interviews
On the basis of the data gathered above, eight studies
were purposefully selected as case studies. Selection was
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with regards to: duration of participant involvement; age
and health status of study participants; whether studies
were facility or community based; whether studies were
based only in Coast Province or multi-centre inter-
national studies; level of risk in studies; and whether any
money was given to participants. A summary of the case
studies is presented in Table 1. Study PIs and/or their
Project managers (n= 11) were individually interviewed
while the fieldworkers of two studies (n= 19) participatedTable 1 Case study details
Study Overall
duration




Perfusion study (PS) 2 years July 2008 2-6 months 4
TB study 2 years Sep 2009 6 months 1
Respiratory infections
I (RSV I)
4 months Jan 2009 Approx 20-30mins 4
Malaria Vaccine (MV) 3 years Jan 2009 3 years 1
Immunology
(Immuno)
5 years 2006 5 years 5
Respiratory Infections
II (RSV II)
4 months Oct 2009 4 months 5
m
HIV study (HIV) 10 years 2006 >2 years 3
Verbal autopsy (VA) >2 years July 2008 30-45 mins 1
Key informant interviews (KIs)in two FGDs. Interviews explored in more detail what
benefits were given to whom and why, how benefits are
communicated to participants and wider communities,
and their experiences, views and recommendations with
regards to benefits and payments.
Individual and group interviews covering similar topics
were held with nine key staff members including com-
munity facilitators, the head of clinical trials, and the re-
search coordinator based at a dispensary in the district
where there has been significant research activity.argeted
articipants
Description of study Study site
00 children • A RCT, severely ill, admitted with
shock. Venous blood draws: admission,
8 hrs, 24 hrs& 48 hrs
Hospital
• Follow up (f/up) day 28/60 after
discharge
500 children • Severely ill, inpatient children with
suspected TB. All children managed
using WHO standards.
Hospital
• Venous blood samples taken; 1 or 2
f/ups decided upon by clinician




• Nasal samples collected using swabs/
nasal wash
000 children • A large Multicenter Vaccine trial. Trial
vaccines injected 3 different times; 5
venous blood draws.
Community
• F/ups at homes every 6 days after
injections; monthly follow up between
injections
000 children • Cohort study of natural malaria
immunity in children, recruited at birth
Community
• 1 annual blood draw but a 5 ml
sample at any fever event
Weekly f/up visits at homes by FWs.
0 household
embers
• A study to identify pattern of
infection
Community
• Children who were born in previous
epidemic and have elder sibling
• Nasal swabbing twice a week at
participants’ homes; saliva samples
once a week
0 • Men who have sex with men (MSM),
enrolled in a longitudinal observational
HIV study.
Community
• F/ups: weekly-month 1, Bi-weekly-
month 2, then monthly for minimum
2 years
• 50 ml blood drawn per f/up
000 p.a. • Relatives of deceased persons
interviewed (30-45mins)
Community
•Interviews done at participants’ homes
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On the 15th of December 2009, a workshop to discuss
current and future policies and practices around payments
and benefits to research participants and communities for
KEMRI/WT studies was held in Kilifi. 48 people attended
the workshop, representing different cadres of staff at the
research centre, including senior and mid-career scientists,
research officers, community liaison staff, field workers,
doctors and nurses. Non-KEMRI participants included the
District Medical Officer (DMO) and nursing officers repre-
senting Kilifi District Hospital. Professor Mike Michael
Parker, a bioethicist and Director of the Ethox Centre at
Oxford University, UK, facilitated the planning of the
workshop and the final plenary discussion.
Given that an important objective of the workshop
was to propose approaches to payments and benefits for
different types of research in Kilifi, the workshop
included : 1) presentation of a review of relevant litera-
ture and the findings of the above audit; 2) six small
group discussions bringing together staff with similar
experience on appropriate individual and community
benefits for a series of hypothetical studies designed
on the basis of the audit (Table 2); and 3) a final
plenary session where issues raised in the small
groups were discussed in more detail. For the small
group discussions, topics allocated to specific groups
to discuss in more detail in relation to each scenario
outlined in Table 2 were:
 Compensation for travel: Groups 1 and 2: field staff
and community facilitators
 Medical benefits to participants: Groups 3 and 4:
research assistants and medical staff
 Collateral benefits to communities: Groups 5 and 6:
senior researchers and MoH managersTable 2 Tasks and hypothetical cases for groups
Task 1: When is compensation due? (All groups) Task 2: Sc
‘It is often said that research should try to balance benefits
and costs/risks to participants such that they are not made
worse off by participation, including that they do not
spend their own money, use their own time or experience
inconvenience that they would not otherwise have. Do
you agree with this? Why or why not? If you agree, how
much cost or inconvenience requires some kind of
compensation? For each of the four research situations












-Is any compensation due? Why or why not? What would
make a difference to your views on whether compensation
is due?






asked to trIn each case, the specific areas of interest for discussion
about each type of study were: should this benefit be given,
and if so what specifically should be given, how and to
whom? Groups were also asked to consider whether there
should be any flexibility and how would this be managed.
Following the workshop, a draft report was circulated
to all participants for their comments and inputs, and
issues documented as needing further resolution taken
up by a small group consisting of two experienced com-
munity facilitators in the research programme (who are
local residents, including the community liaison man-
ager), a clinical trials manager (who is also a clinician),
and two social scientists (SM and VM).
Data management and analysis
All audit interviews were audio-recorded and tran-
scribed verbatim shortly thereafter. Three authors inde-
pendently identified key themes, and following
discussion agreed on themes to group key data. Sum-
maries of data were used to develop the ideas and dis-
cussion guides for the workshop. At the workshop, notes
were made by specially allocated note takers from both
the small group and plenary discussions. These notes
were drawn upon by the same three researchers to high-
light areas of agreement, and areas of debate and dis-
agreement requiring further discussion or research by
the small group formed to take forwards discussions and
agreements post workshop.
Findings
In this section we bring together the data from the audit
and the workshop, to illustrate what is happening on the
ground in Kilifi regarding each major form of benefit or
payment, including challenges and negative impacts, and
views on what should happen. Following an overview ofenarios (one per group)
interviews about health beliefs taking at least 2 hours
taking 30–45 mins with mother and finger prick blood sample from a
on one occasion only
study. In addition to screening and vaccination visits, intervention and
ups are asked to attend for follow up visits 6 times over 2 months
accination then 6 monthly for 2 years. Free medical care for acute
t illnesses is provided for study children 2 years.
trial. A study on KEMRI ward of a particular type of treatment for severely
After discharge, the child should be brought back for follow up once to
where a single small venous blood sample will be taken and any health
child has will be addressed.
dy with well children. A study where a group 200 children under 5 years
e area will be followed up for 5 years to assess development of
o malaria. Children are visited weekly to check for fevers, medical care is
ee at the nearest health dispensary for all acute intercurrent illnesses for
ren and once a year a venous sample is taken. If children become
ing the study and cannot be managed at the dispensary, they will be
avel to KDH for further treatment.
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turn at experiences with: medical benefits, travel costs,
other benefits and compensation for time. The cross-
cutting issues relevant to developing guidelines, in-
cluding the importance of community level collateral
benefits in low income settings, and the need for
flexibility and careful consideration of communication
issues in policies and procedures, are highlighted in
the discussion.
Types and levels of benefits offered
From reported data in the audit, with the exception of the
verbal autopsy study, which involved a 30–45 minute
interview only with adults in their homes, all studies
offered some form of benefit or payment to participants.
Table 3 shows the benefits and payments given by the
seven studies, illustrating not only the diverse range, but
also the centrality of direct and collateral medical benefits,
and the reimbursement of travel expenses. Other types of
benefits included provision of food for individuals, and
other small gifts such as books and pens. In general, the
levels of collateral benefits for individuals increased with
studies seeking to involve participants for longer, and
where an (experimental) intervention was involved. For
example the benefits for individuals in the malaria vaccine
study (MV) and the Immunology study (Immuno) were
greater than that of the TB study or the RSV study.
Overall the workshop discussions on the scenarios
supported the general trend of more benefits for longer-
term/higher risk studies. There was a clear overall agree-
ment that participants should not be made worse off by
their participation in any research. It was felt that if the
short and low risk activities illustrated in scenarios 1 and
2 in Box 1 had no costs – direct or hidden – it was ap-
propriate not to offer any benefit or payment beyond an
appeal to aspirational benefits, and showing common
courtesy through for example providing refreshments
and research findings, where appropriate. An area of de-
bate (discussed in more detail below) was how much
time needs compensation, and what kind of compensa-
tion is appropriate for that time. The recommended
range of collateral benefits for scenarios 3 and 5, both of
which require repeated interactions with well children,
were relatively high, to compensate for the relatively
large amount of time involved in these studies, and to
minimize drop-outs and monitor health. Beyond the
payment of direct costs and showing common courtesy,
the main benefits considered to be appropriate were
diagnosing, treating and referring study children, and
providing community benefits such as strengthened dis-
pensary services. The debate (also discussed in greater
detail below) was on whether siblings and parents can
access health care benefits, and how this is balanced by
strengthening community benefits. In scenario 4, therewere considered to be significant direct benefits built into
the trial design, and significant community benefits as part
of wider support to the hospital, and some concern that
continuing to increase the collateral benefits to participants
might compromise voluntariness in informed consent.
Experiences with regards to specific benefits, payment
and other items
Medical benefits
There was a general perception that medical services are
often the most appropriate form of benefit given that health
care is close to our area of interest and expertise, and that
this form of benefit minimizes the move towards a
commercialization of the research encounter. All of the
seven studies offering benefits provided some form of direct
medical benefit to study participants (Table 3), with details
of the package depending on the study. In addition to free
treatment of the disease or problem of interest (for example
clinical shock, TB, malaria, RSV, or HIV), study participants
usually received free consultation and treatment for other
minor or acute illnesses over the course of the study, in-
cluding out of hours, and in some cases (e.g. PS) without
queueing? Other treatment included in most studies were
referral of more complex or chronic illnesses identified over
the course of the study to other government facilities, in-
cluding vehicles or transport to the referral facility (PS),
costs of doing diagnostic tests e.g. X-rays (HIV) and
medical fees (Immuno, MV).
All studies included collateral medical benefits to non-
participants through for example strengthening of the gen-
eral services of a facility for all patients with a similar prob-
lem. Specific support offered included improved laboratory
facilities for TB tests (TB); provision of emergency care
training for all intensive care ward medical staff (PS),
provision of weighing scales, haemacue machines, i-STAT,
and thermometers (PS); and provision of medical staff and
refurbishment of existing health facilities (MV).
The audit and workshop group discussions highlighted
several challenges related to medical benefits in studies.
One set of concerns was how much of a benefit indivi-
duals actually get from a specific study beyond standard
of care. The first challenge is that the standard of care in
the paediatric wards is already high relative to other dis-
trict hospitals as a result of programme wide support
(see background); support that is described by some se-
nior researchers both as a collateral benefit and as a ne-
cessity for researchers to feel comfortable to conduct
research in an area with so many unmet health needs,
and to minimise inducement. The overlaps between
standards of care, collateral benefits and study require-
ments were illustrated in an interview:
We took that approach right from the beginning that
we would just first set up a platform for TB diagnosis
Table 3 Benefits provided by specific studies (beyond standard of care locally)
Study Direct medical benefits for
study participants
Collateral medical benefits Transport/fares Other benefits
Perfusion study
(PS)
• Hourly monitoring of patient,
potentially leading to more
prompt identification and
treatment of other acute illnesses
• Additional emergency and triage
training (ETAT) for all study staff
on high dependency unit (HDU)
• Fare for follow-up on
days 28 and 60 after
discharge
• 100$ shillings for lunch
on days 28 and 60 day
follow-up visits
• Lab and clinical equipment
support to health facilities• Participants do not queue at
hospital when sick between
follow-ups
• Potentially more rapid referral
to provincial referral hospital
TB study • Free management of TB,
contact-tracing and
management of infected adults
• Enhancing diagnostic and
laboratory capacity of clinic





• Free treatment of all acute
infections including payment
of hospital bills
• Physical upgrading of
dispensaries in which trial is
taking place, and laboratory
clinical support including
provision of vaccines where
necessary
• Fares or lifts in KEMRI




• Regular screening of children
for anaemia, de-worming
• KEMRI cars also help in
times of emergencies
• Referral of chronic illnesses
and those that cannot be
handled at the facility
• Resuscitation equipment for use
by all dispensary patients
• Uninterrupted access to EPI &
rabies vaccines, and Hep B
even in cases of MOH stock-
outs
• Study personnel man facility
when MOH staff are away
Immunology
(Immuno)
• Weekly testing of children for
fevers
• Study personnel man facility
when MOH staff are away
• KEMRI cars or taxis sent
to take sick participants
to hospital (day/night
respectively)
• Milk, bread for children
during annual bleeds.
• Prompt, timely treatment of
all acute illnesses
• Notebooks and pens
for the children
• Disease surveillance for the
Ministry of Health
• Referral of chronic cases to
government facilities
RSV 1 • Free treatment of all acute
infections
• Lab and clinical equipment
support to health facilities
• N/A (participants came
to facility for own
reasons)
• Sweets for children
• Antibiotics and gloves supply for
community facilities
• Disease surveillance for the
Ministry of Health
RSV 2 • Free examinations, medical
treatment of all acute
infections
• Fares to hospital for
treatment
• None
• All medical bills settled by the
study
HIV • Free screening & treatment
for STI’s, HIV tests even in the
absence of symptoms
• Access to services without
stigma as a result of careful
training of all staff
• 600 ($1.30) shillings fares
provided at a flat rate
• Free lubricants
• Food tickets for those
on ARVs and the very
poor• ART started at earliest possible
time
• HIV disease monitoring and
support counselling
• Free condoms and Hep B
vaccines
• Provision of vaccines e.g. rabies
and Hep B
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the study, but also pretty fundamental to the care for
children so we set up this platform and we have made
it part of standard of care for children with [. . .] soany child who is referred with suspected TB or is
admitted with symptoms and signs consistent with
suspected TB gets worked up for TB (IDI No. 1,
Researcher).
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contributed to by individual studies, it was argued that
studies often do involve greater observation and investi-
gation in study children, and that this can lead to
improved diagnosis and care even within a relatively well
equipped ward.
The second challenge is that while researchers
describe free treatment as a benefit, there are national
policies for exemption of charges for all children aged
less than five years. Nevertheless, it was recognised that
across the country there is relatively little adherence to
exemption policies [30,31], and therefore that free care
remains a significant benefit. When combined with
transport, or reimbursed fares (discussed next), the
medical benefits were therefore felt to be quite signifi-
cant especially for the scenarios 3, 4 and 5. PIs working
on similar studies reported that non-participants regu-
larly asked to join studies, illustrating that benefits are
valued.
Another set of concerns related to medical benefits
concerned who is eligible and where they can seek
treatment from. Regarding the former, the challenge
was what to do if parents brought other sick family
members for free treatment, or even their neighbour’s
children. Interface staff who were approached by indi-
viduals not formally eligible for this benefit sometimes
found it difficult to refuse a needy case, but were also
concerned that providing care would start a precedent
for other families and studies. The dilemma could be
particularly difficult for members of the index child’s
family, with families reportedly commenting that re-
search can introduce unfairness within households,
and for example accusations that researchers are inter-
ested in the child but not the person who gave birth
to him/her:
In case a parent has been involved in an accident and
it is a parent to a study child, the vehicle cannot be
offered....they [community members] tell us, “mtoto
hakujizaa mwenyewe, alizaliwa na mimi” [this child
didn’t give birth to him/herself, I gave birth to him]
(FGD no 1; fieldworkers)
Some study clinicians reported that attending quickly
to study children while referring their sick sibling to a
long hospital queue felt wrong, and that they would
sometimes treat the sibling out of compassion (KI)
even where study policy did not support this action.
Others would diagnose the non-participants’ problem
and then refer them to the hospital pharmacy to buy
drugs; thereby at least saving the parent queuing time.
But this was difficult where the parent had no money
to buy prescribed drugs. Staff described such dilem-
mas, and having to stick to standard operatingprocedures (SOPs) set by people who were not present,
as incredibly stressful:
Even we FWs sometimes hurt inside. . .you may see
me growing thin and yet it is stress from the job
(laughter). . .you are having this enormous burden all
on you. . .(FGD no 1; fieldworkers)
These challenges were exacerbated by some studies
being more inclusive and flexible with regards to assist-
ance of other family members than others. While this
would be expected with such different studies, there
appeared to be both a lack of standardisation across very
similar studies, and problems in communicating clearly
about these differences. Related challenges were confu-
sion and sometimes irritation regarding the timing of
medical benefits; in some cases participants can receive
free treatment at any point over the course of the study
(MV), in others it is only when they come back for a
specific follow up visit (e.g. PS; TB). The latter can feel
short changed, and may be taunted by others:
. . .they [non-participants] would tell the participants
that, “look, it is only when KEMRI needs to draw
blood from your child, that they send you vehicles,
but when your child is sick, you trek to hospital just
like the rest of us”. . . (FGD no 1; fieldworkers)
This phenomenon of local interpretation of perceived
differences in benefits between studies leading to confu-
sion and tensions was general to all types of benefits, as
discussed more below. One outcome was potential re-
fusal to participate in studies with less tangible benefits:
[we get told] “No, you are not coming to this house to
ask any questions. . . you take everything [benefits] to the
other homes and here you only come to ask
questions. . ..No, go to that house. . . that is your
house. . .(FGD no 2; community facilitators)
some would say that, “we are not in the project but we
are also seen by the KEMRI doctors (it doesn’t matter
that you are seen first). . .and we also get lifts-just like
you. . .but only you struggle in the project”. . . (FGD no
1; fieldworkers)
At the workshop it was felt that for longer term studies,
medical benefits provided should be greater than for short
term studies, and that these medical benefits should be
extended to participant siblings and other family members
wherever possible, not least to help strengthen the rela-
tionship with participant families and help ensure reten-
tion. There was agreement that overall, support to siblings
should at least ensure that the benefits to individuals are
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care, and that with referrals to other facilities, all costs for
the first visit including treatment should be covered. With
regards to inter-current illnesses experienced by partici-
pants between planned visits in longitudinal studies, for
example following discharge from the district hospital,
there was a general agreement that these should not be
paid for, because there are already significant benefits built
into studies, and a requirement for this support would be
impossible for many studies.
Travel costs
All of the seven studies aimed to ensure that patients did
not incur any travel costs (Table 3). Travel costs were
therefore either avoided (for example by organising re-
search centre transport to collect people from their homes
to facilities; MV study) or refunded. In general, costs were
not met for travel that would have happened in the ab-
sence of the study. For example fares were not refunded
for participants in the TB or RSV studies for their first visit
to the hospital, because this travel occurred as part of care
seeking before they were recruited in the study.
There were differences across the studies with regards
to how fares were refunded, at what level and what spe-
cific costs they were supposed to cover or compensate.
For example some studies (e.g. Immuno) would give out
money in advance, providing funding at each visit to
cover the travel costs of a subsequent attendance. Others
(e.g. MV) only refunded return fares on arrival for the
research visit. Some studies reimbursed set amounts
based on known costs of public transport from the parti-
cipant’s area of residence, while others refunded actual
amounts claimed on the day, in some cases only on pro-
duction of a receipt. Some studies added a small ‘top up’
to allow for purchase of refreshments for the trip, and
some paid a small fixed amount of money to those who
walked to the facility because they lived close by or
could not access public transport. One study (HIV)
incorporated into standard ‘travel costs’ some compensa-
tion for time spent on the research activity.
Another difference across studies was exactly who had
fares covered, and for what services. For example, costs
could include those for the child only, or other siblings
that the parent might need to travel with, and for one or
two parents; and sometimes studies allowed for trans-
port costs in unexpected health emergencies. Emergency
assistance was generally offered only in consultation
with health facility nurses, and only by the longer term
studies out of normal working hours, primarily as a ‘hu-
manitarian response’ (MV) or as a way of ‘being part of
the community’ (Immuno).
‘We have been encouraged by the MoH not to set up
a parallel system. . . [they] were very categorical that ifsomebody is unwell they should follow the normal
procedure- go to the nurse in the health facility who
will call the ambulance. . .also because of medico-legal
reasons. . .the ambulance comes with a nurse. . .there
is some sort of first aid at hand. . .(IDI no 8;
researcher)
The audit revealed significant challenges with (re)pay-
ment of travel costs, including concerns associated with
different approaches across studies, and between the in-
stitution and others operating in the area:
‘Even with fares; a study will give exact fare, another
one will give extra - like one and a half the amount
that people are charged, so sometimes it brings
problems and you know sometimes they are in one
study when they complete then maybe another child
is in another study, so they are like, “why is it that I
was given double fare and now you are giving me only
one way” (laughter). . .’ (IDI no 6; clinical officer)
As for medical benefits, this quote hints at the mis-
trust that can be introduced by these different
approaches, or at least by them being inadequately com-
municated. Another challenge was introduced by per-
ceived lack of fairness or even sense in not extending
transport support beyond the index child in a study, as
noted above.
Specific concerns raised with giving fares long in ad-
vance of appointments were that:
 where money was spent on other pressing needs,
parents would sometimes avoid appointments or
otherwise fail to turn up, leading to relatively
expensive follow up visits to homes, and possibly
embarrassment for families, or
 parents may feel unable to change their minds about
coming to follow-up visits, having already accepted
the money at an earlier stage.
 Other travel payment concerns were that transport
receipts were often difficult for parents to obtain,
and that amounts claimed were sometimes higher
than those incurred. On the other hand collecting
participants from home with research vehicles
included the possibility of introducing long waits
where arrival time at homes were difficult to predict,
and difficulties with handling others needing lifts at
the same time. Finally, there were some reports of
fieldworkers using their own funds to assist
participants and finding it difficult to ask for
reimbursement from the study team.
At the workshop it was agreed that transport costs in-
curred specifically for research must always be paid/
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time spent and other needs on the journey (e.g. drink/
snacks). There was a suggestion that to maximise fair-
ness and clarity, to minimise potential to negatively im-
pact on informed consent and to simplify administration
systems, studies should:
 Set repayments based on where participants live,
regardless of whether they actually use that public
transport on that day, and therefore even without
receipts. The amounts can be calculated depending
on the zone participants live in surrounding
research facilities,a with everybody from that zone
given the highest expected cost from that zone.
Amounts per zone should include a small additional
amount to actual expected transport cost, to cover
for refreshments or unexpected costs for the
journey.
 Allow participants to choose whether they wish to
be paid in advance for a future visit, or during that
future visit
 Ensure travel is reimbursed for one parent and the
index child if he or she is five years or above.
Other non-medical benefits
The most common other items offered by studies were
food and snacks (five studies) offered when participants
were visiting facilities away from home, or – less com-
monly – when significant amounts of time were taken
within households. These were either to compensate for
missed meals, as a token of appreciation, or to calm chil-
dren (sweets and biscuits). Food was provided ready to
eat (MV, Immuno, RSV, MV), as money for families to
buy their own food (PS), as tickets to exchange for food
at selected outlets (HIV), or as dry food for participants
to cook themselves as convenient (reported in cross-
cutting interviews). Other benefits included notebooks
and pens (Immuno) for school-going children. In HIV
studies participants were also given T-shirts, lubri-
cants and legal services of a lawyer where charged
with minor non-criminal offences such as loitering.
Some people also considered the hiring of field work-
ers from the local community as a significant com-
munity benefit.
Specific challenges with regards to these benefits (be-
yond those of other benefits of the amounts and who
received these) were reports that some participants felt
that very small benefits, juices and biscuits for instance,
belittled their contribution, and led to them being
taunted by others in the community. A particular con-
cern with regards to t-shirts distributed by one study
(HIV) was that some participants reportedly did not
want to wear them as they were concerned that they
would be stigmatised as having HIV/AIDS.Financial compensation for time
At present, compensation for time is through the
inflated fares described (or fares being given where they
are not strictly needed), or through medical and other
benefits. There were concerns raised through the audit
that compensating for time through inflated transport
costs, particularly where no transport costs were actually
incurred, raised confusion and suspicion. For the HIV
studies, there were reports that this approach risks
people falsifying information in order to obtain cash, or
concerns about confidentiality.
some would even lie. . . they would ask, “how come
you are there, what did you say?. . .Okay, these are the
kind of people they want?. . .Okay, I will just go and
say this is what I am. . .I would say I am MSM. . . I am
a sex worker- that is what they want”. (IDI no 7;
research manager).
Actually for us, maybe one of the things is the
variation of reimbursement. . .you will say that the
uninfected cohort, you will give 350. . . then you have
another one being given 500. . . then you have
someone on the trial getting 600. . . volunteers
challenge us. . .they really want to know why is it that
so and so gets 500. . .and I can’t tell the person what it
is about.. I can’t break confidentiality about their
status (IDI no 7; research manager).
While the latter concern may be particularly applic-
able to research in stigmatised diseases or popula-
tions, lack of clarity about what the payments are for,
particularly where somebody has walked to a facility,
was reported for several studies, and in the workshop.
This lack of clarity, in some cases linked to a broader
misinformation about what the research is about and
how it differs from standard health checks or treat-
ment, can contribute to disputes within households
(for example, concerns from husbands about where
the mothers of participant children have received
money from and why), and fuel rumours around the
aims and objectives of the activities (for example,
concerns about whether KEMRI is ‘buying blood’).
. . .and what that does to the home dynamics. . . the
decision-making. . .when you give the woman the fare,
and ideally a married woman here is only supposed to
be supported by the husband. . .she is only supposed
to get money from the husband; so here is KEMRI
coming to give her money. . .exactly what are you
doing to the power relations between the woman and
the husband. . .on top of that you are giving her more
than she needs for fare. . .(IDI no 9; community
facilitator)
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no matatus [public transport vehicles] in this area yet
you say that this is fare. . .no. . . just tell us what this
money is, but don’t you say that it is fare”. . .(IDI no
11; nurse)
It was agreed at the workshop that time costs – including
what somebody might be doing in that time, such as pre-
paring a meal or earning an income - should be properly
considered in research planning because these costs are
often under-estimated. It was recognised for example that
families may often stay at the dispensary waiting for a one
hour assessment for far longer than an hour, and that field
staff may turn up late to a household for an appointment,
causing delays. It was agreed that appreciation and
common courtesy should be maximised by minimizing
inconvenience to participants, and – especially where the
participant leaves home - considering the need to provide
snacks or lunches. However the question of if and how to
provide a reasonable allowance in cash for ‘lengthy’ re-
search activities (either in homes or away from them) was
highly complex, given the different types of income gener-
ation people have, diverse incomes and the different
approaches research staff took to the issues. Given that
there was no simple calculation that we could draw on at
the workshop, and that there were concerns and debates
about moving towards a more commercial relationship
with participants/communities, the area was recommended
for further careful research and discussion. Subsequently,
the small group formed to take forwards workshop findings
have suggested that where significant individual time is
taken (for example the exceptional cases of an overnight
stay in a facility that would not otherwise be necessary),
past research in our area supports payment in accordance
with national guidelines on minimum daily unskilled wages.
At the time of writing this was 300/= or GBP 2.30 per day
in an urban setting.
Discussion
There is general consensus that fair benefits are essential
in international health research, but the exact nature of
benefits that should be provided to participants and
communities, and their mode of provision, are not
clearly defined, and often strongly contested. There has
been little detailed research on experiences and chal-
lenges with benefits on the ground, particularly from
low-income settings, to feed into on-going debates. We
explored benefits and payments offered for a diverse
range of studies within a large long-term multi-
disciplinary research programme in Kenya, using both a
descriptive and consultative approach. Although not all
relevant parties were involved (most notably absent were
study participants or their parents, community represen-
tatives, health workers and ethics committee members),we were able to include a broad range of programme
staff, including the voices of those who are often
excluded from policy discussions: the interface staff who
explain and administer benefits and payments to re-
search communities; many of whom are from those
communities themselves.
We did not cover some types of collateral benefits
from studies to communities, such as employment of
local personnel, capacity strengthening of researchers
from the region, nor post trial benefits. Also not dis-
cussed in detail were the collateral benefits such as clin-
ical staff and services funded by the programme to the
paediatric wards at the district hospital, and to govern-
ment health centres and dispensaries in which research
is conducted. Nevertheless, we believe that we have
gathered sufficient information to begin to draft institu-
tional guidelines on what ‘ought’ to be done in our set-
ting for studies (both procedural and substantive
elements), and to highlight some areas that need further
research and discussion.
Challenges with current practice
Our interviews and interactions helped us learn about
some of the realities of administering a wide range of ben-
efits and payments on the ground (medical, transport,
food and other). A picture emerges of current practice
being appreciated by staff and communities, but also
being associated with significant issues and challenges
which have received little attention in the literature, rela-
tive to concerns about undue inducement. Costs to parti-
cipants that may not be considered for example are lack
of common courtesy in research encounters, and amounts
of time spent waiting or travelling for research appoint-
ments. These costs can mean that participants, rather
than being induced into research, are potentially under
compensated for their role in research. Concerns of
researchers to minimize this possibility and even to intro-
duce a benefit rather than simply a compensation to parti-
cipants, can contribute to the payment of inflated or
unnecessary fares described in our study. The complexity
involved in apparently simple reimbursements has
recently been noted for another Kenyan setting [32]:
Underneath the seeming obviousness of the concept of
‘reimbursement’ many other considerations were at play
and informally negotiated. These included questions of
justice and ethics, and personal commitment to provide
some help for poor study subjects, but also budgetary
constraints, competition with other groups for
participants, and concerns with recruitment rates and
participant retention [32; page 50]’.
The transport issues noted above illustrate the com-
plexity in practice in defining benefits, and specifically in
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transport fare issues in our study also illustrate how ben-
efits and payments can in themselves also exacerbate or
introduce new inequities, conflicts and rumours within
households and communities, especially where benefits
are both significant and visible. Even where benefits have
been carefully considered for the participant him/herself
in one study, these considerations might be undermined
by a household situation (for example if a mother has to
queue twice: once for a study participant and again for
another sibling), or by other studies being conducted by
the same organisation (for example another similar study
offering different levels and types of benefits). In this
way, the wider research and social context is key to the
way that study specific benefits work out in practice. For
researchers, these realities may be both obscure and
complex, supporting the need for locally relevant institu-
tional guidelines aimed at ensuring that participants are
adequately compensated, that intended benefits actually
reach participants and communities, and that wider con-
cepts of fairness are supported.
A middle ground between micro and macro justice issues
in approaches to benefits
It became clear over the course of the audit and work-
shop that research staff generally approach benefits and
payments deliberations in two ways: a) focusing on en-
suring that participants do not incur overall costs, with
their overall approach being one of research being based
on good will and partnership between researchers and
research participants or communities, underpinned by a
concern about moving away from this type of relation-
ship towards a more commercial one; or b) aiming to
maximise benefits as far as possible to participants, given
the relative wealth of the institution and poverty of many
community members/research participants.
Overall, an appropriate compromise or middle ground
that emerged for our context was ensuring that direct
benefits to individuals are primarily medical (rather than
financial or for example food), and that there is an effort
at all times to maximise collateral medical benefits to
whole communities, through developing strong colla-
borations with the Ministry of Health. The collateral
benefits can be offered both by specific studies as illu-
strated by many of our case studies in this paper, but
also at a programme wide level through the kind of sup-
port that is currently provided as summarised in the in-
stitutional section under methods in this paper. This
compromise it was hoped would avoid a commercial re-
lationship with participants, and protect and strengthen
a key relationship with the MoH. This approach might
be considered one way to tackle micro-level justice
issues (for example fair benefits and compensations for
research participants) in a way that recognises macro-level justice concerns (for example historical grievances
and global inequities that perpetuate poverty and ill
health), as one of a set of approaches to benefit-sharing
at both the micro and macro levels [12,21,23].
There are three important issues to note in proposing
this balance. Firstly, while we are describing here appro-
priate direct and collateral medical benefits, we must
recognise that all ‘benefits’ that have to be given to parti-
cipants or communities to ensure scientific validity, pre-
vent study-related harms or address study related
injuries, are not benefits at all. Beyond these basic
requirements, many other medical ‘benefits’ described as
appropriate by our participants might equally or more
accurately be framed as ancillary care responsibilities or
even obligations.
This is particularly given that we are a long term, well
resourced research programme (indicating relatively
strong relationships and opportunity and capability to
provide care), operating in a low income setting facing sig-
nificant basic health care challenges (indicating urgency of
health care needs) [17,19]. Secondly, we recognise the risk
that medical benefits increase the potential for therapeutic
misconceptions (TMs) arising [29]. Nevertheless we see
this TM potential as emphasising the need for careful
communication about studies and any included care or
benefits rather than as undermining the arguments to pro-
vide the benefit or services. Thirdly, we recognise the im-
portance of very careful negotiations and discussions
within the institution, and with key Ministry of Health
representatives, to ensure that sustainability of additional
support is assured, and even that pre-existing services are
not undermined in the longer term.
Towards institutional guidelines to support clarity and
transparency in benefits and payments
The need for flexible guidance to support clarity and
transparency in benefits and payments was emphasised
as crucial by research staff at all levels. It was felt that
institutional guidelines could help develop agreed, con-
sistent and rational approaches and explanations on ben-
efits and payments for the main types of study
conducted, minimize differences between similar pro-
jects, and thereby reduce perceived unfairness. It was
also felt that institutional guidelines would potentially
reduce staff anxiety associated with conducting research
in situations of poverty and hardship. The need for
strengthened communication about benefits and pay-
ments, including about differences between different
types of studies and reasons for these differences, was
also highlighted as essential to minimise perceptions of
unfairness. The specific issue of benefits and payments
is clearly therefore key to include in broader community
engagement plans and consent SOPs for studies and the
programme overall [28,33].
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reimbursement and benefits for research participants
and communities. In these guidelines, for all studies
researchers will be prompted to:
 Carefully consider the real time, inconvenience and
expenses for participants to ensure that these are
not underestimated
 Ensure that common courtesy is demonstrated
throughout studies by for example minimising
inconvenience, ensuring good communication, and
providing refreshments.
 Where payments are made, base these on time,
inconvenience and expenses for each study and
participant, rather than on a flat rate. In calculating
fare reimbursements to local residents, offer rates
based on zones surrounding a given location, with a
small allowance for refreshments, and make
payments regardless of production of a receipt. In
this approach we differ with that of for example the
South African Medical Research Council guidelines
which set a flat rate policy per visit for clinical trial
participants. The flat rate approach has been
variously critiqued for being excessive,
inappropriate, unaffordable to non-industry funded
trials, and ultimately unfair: participants are paid the
same amount but do not do the same things or
incur the same expenses [20].
 Recognise that individual participants want their
contributions to research to be adequately
acknowledged, and that what we might be currently
calling medical benefits are in fact responsibilities or
obligations in our setting (discussed more below).
Ensure that actual benefits for individuals are
weighed against potentially introducing intra-
community conflicts, and that institutional emphasis
IS PLACED where possible ON providing health
benefits to broader communities (through
discussions with MoH managers and other relevant
stakeholders).
To facilitate thinking about specific benefits in relation
to a spectrum of study types our guidelines will distin-
guish between four types of studies 1) clinical trials; 2)
sampling only involving no intervention; 3) observational
studies involving no sampling or interventions; and 4)
interview only studies. For the shortest and least incon-
venient studies (for example, a 45 minute interview only
study), the key requirements will be communicating
effectively about the study, minimising inconvenience and
ensuring common courtesy, including returning results
where appropriate, rather than offering study benefits. As
participants’ inconvenience and time contribution
increases, increasing benefits are likely to be appropriate,for example for clinical trials (such as phase 2b and 3
vaccine/drug trials with prolonged follow up) and longer
term observational studies. The main argument for
increasing benefits for these studies in our setting is linked
to concepts of compensation and for a stronger require-
ment for reciprocity in the studies with longer and more
intensive relationships [34]. At the same time, we are
aware of a counter-argument that this might introduce a
perceived or real unfairness across studies (with those we
are more engaged with receiving for example better health
care), and that participant ability to withdraw might be
compromised [35]. Furthermore, it is not necessarily
straightforward to argue that duration and intensity of
relationship should influence research participants’ bene-
fits [36]. We try to consider and counter these concerns
through strengthening wherever possible programme wide
and study specific community benefits, as described
above. A relatively complex area that needs further work
is how much time needs compensation, and what form of
compensation is due for that time. Given the overall con-
cern with setting precedents and distorting the research
relationship into a commercial one, this will need particu-
larly careful review and monitoring.
We plan to finalise our guidelines, and check these with
research staff and other key stakeholders such as members
of the national ERC, community representatives and MoH
staff. If agreed, we will begin to implement guidelines with
careful monitoring of impacts on individuals, families and
communities, and front-line and senior research staff. Im-
portantly, the communication of decisions made regarding
benefits and payments will have to be passed within teams
to the frontline staff and between research teams and
community members as a key part of broader community
engagement plans and activities. We hope that this
process will help us to continue to learn about this critical,
complex and contested area. In so doing we hope we can
continue to learn from and feed into experiences and
guidelines from other settings.
Conclusion
We drew on interviews and a consultative workshop to
develop draft guidelines for our programme that focus
on the direct and collateral benefits offered to study par-
ticipants and to other community members over the
course of the conduct of studies. The difference in bene-
fits and payments currently offered for similar studies in
our programme, and some perverse outcomes associated
with levels and types of benefits, and how they are admi-
nistered, support the importance of this initiative for our
programme and potentially for other similar settings.
Also supporting this initiative is the complexity in distin-
guishing on the ground between compensation and ben-
efits, and between medical benefits and obligations and
responsibilities. We reiterate that consideration of these
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siderations at both the micro and macro level of benefit-
sharing by individual studies and the institution, including
post-study benefits, aspirational benefits from research,
and capacity strengthening in research and of health
systems.
Endnotes
aZones to be created for areas with similar known
costs to the facility
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